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Abstract
Background Fully covered self-expandable metal stents
(FCSEMS) have been used as a rescue therapy for several
benign biliary tract conditions (BBC). Long-term stent
placement commonly occurs, and prolonged FCSEMS
placement is associated with the majority of the compli-
cations reported. This study evaluated the duration of
stenting and the efficacy and safety of temporary FCSEMS
placement for three BBCs: refractory biliary leaks, post-
sphincterotomy bleeding, and perforations.
Methods This was a retrospective case series with long-
term follow-up of 25 patients who underwent FCSEMS
placement for BBCs. This study included 17 patients
with postcholecystectomy refractory biliary leaks who had
previously undergone unsuccessful sphincterotomy and
plastic stent placement, 4 patients with difficult-to-control
postsphincterotomy bleeding, and 4 patients with a perfo-
ration following endoscopic sphincterotomy. Stents were
removed according to clinical evidence of problem reso-
lution. The review included stenting duration, safe
FCSEMS removal, clinical efficacy, complications, and
long-term outcomes. During the follow-up period, ERCP
and cholangioscopy procedures were performed to exclude
the possibility of bile duct lesion development.
Results Complete resolution of the initial condition was
achieved in all patients. Patients with biliary leaks had a
median stent duration time of 16 days (range 7–28 days).
Patients with bleeding had stents removed after a median
time of 6 days (range 3–15 days). Patients with perfora-
tions had their stents removed after a median time of
29.5 days (range 21–30 days). There were no complica-
tions related to stenting.
Conclusions Temporary placement of a FCSEMS for
30 days or less is an effective rescue therapy for refractory
biliary leaks, difficult-to-control post-endoscopic sphinc-
terotomy bleeding, and perforations. Duration of stenting
should be different for each type of condition. Stents can be
safely removed, and short-term stenting is associated with
the absence of early and late complications.
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Since its introduction in 1968 [1], endoscopic retrograde
cholangiopancreatography (ERCP) has evolved into a
sophisticated therapeutic endoscopic examination, and the
placement of biliary plastic stents has become one of the
cornerstones of the procedure. Initially, due to the small
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diameter of the working channel of the endoscope, it was
only possible to place small-caliber plastic stents. How-
ever, the 1982 [2] development of duodenoscopes with
4.2-mm working channels allowed the use of large-bore
(10–11.5-French) plastic stents. Ten-French stents are now
the standard caliber, because use of 11.5-Fr plastic stents is
more technically challenging and does not increase stent
patency [3]. Plastic stents are routinely used to treat benign
biliary conditions (BBCs) such as biliary leaks [4–6],
strictures [7], postsphincterotomy bleeding (post-ES
bleeding) [8], and perforations [9, 10].
Clinically significant biliary leaks can occur after
hepatobiliary surgery and are the main cause of postop-
erative bile leaks following laparoscopic cholecystectomy
procedures [4, 5]. Despite the widespread use and efficacy
of ERCP in the diagnosis and treatment of biliary leaks
[4–6, 11, 12], a variety of percutaneous and surgical
treatments have been proposed [13, 14]. Biliary sphinc-
terotomy alone [5], use of large-bore transpapillary biliary
stents [5], or a combination of both therapies have become
the first-line interventions for the treatment of bile leaks
[4, 5]. Although there is no consensus as to the optimal
endoscopic intervention, recent data suggest that a com-
bination of biliary sphincterotomy and placement of a
transpapillary biliary stent has a better outcome for the
treatment of high-grade biliary leaks [4, 14]. Endoscopic
management of bile leaks is safe and efficacious with a
high success rate [4–6, 11, 12]. Nevertheless, there are
reports of difficult-to-treat, refractory bile leaks that
require multiple endoscopic interventions and sometimes
surgery [4, 5].
Endoscopic sphincterotomy (ES) is a fundamental pro-
cedure of therapeutic ERCP. Complications following ES
can include bleeding [8, 9, 15] and perforations [9, 10]. The
incidence of post-ES bleeding varies from 0.76–2 to
10–48 % [8, 15], depending on the definition applied. Post-
ES bleeding is classified as immediate or delayed accord-
ing to the time of presentation [8, 15, 16], and it is
associated with increased morbidity and mortality [8, 9, 17].
Endoscopic treatments include injection treatment, thermal
therapy, endoclips, and balloon tamponade, which can be
applied individually or in combined treatments. These pro-
cedures are associated with the placement of large-bore
plastic stents to further tamponade the bleeding site and to
maintain biliary drainage [8, 15]. In a small percentage of
cases, refractory bleeding requiring angiographic emboliza-
tion or surgery occurs [8, 15]. Another post-ES complication
is perforation, which occurs in 0.35 % and 0.48–0.72 % of
cases [9, 10]. Although conservative management with
intravenous antibiotics, fluids, a nil-by-mouth regimen, and
the placement of large-bore plastic stents is efficacious,
surgery is sometimes required [9, 10].
Because the use of plastic stents is not able to resolve
problematic cases, gastroenterologists have looked to
self-expandable metal stents (SEMSs), which have large
diameters and demonstrate a prolonged duration of
patency, as a rescue therapy for difficult-to-treat patients.
Because uncovered SEMSs soon become embedded into
body tissues, their removal is difficult, if not impossible,
which limits their use in BBCs [3, 18, 19]. Covered SEMS
were designed to prevent tumor ingrowth and reactive
tissue hyperplasia through the stent mesh. This cover
prevented the metal from embedding into the biliary tract,
allowing for removability [3, 19–22]. The first covered
stents were coated in the middle and had both ends
uncovered. Although efficacy has been shown [19–22],
studies using partially covered SEMS in several BBCs
reported early complications, including duodenal or
proximal migration and pancreatitis [21]. Later compli-
cations also occurred and included duodenal or proximal
migration and cholecystitis [20, 21]. Furthermore, because
the initial portion of the partially covered SEMS can be
embedded in the bile duct, its removal can be difficult,
particularly in cases of proximal migration. This embed-
ding can result in late stricture formation at the site of
embedding [19–23].
Fully covered SEMSs (FCSEMSs) were designed to
maintain long-term patency and can be used to treat
BBCs. The full coverage of the stent decreased the
incidence of complications and made stent removal safer
and easier [3, 24–26]. Although not approved by the
Food and Drug Administration, temporary FCSEMS
placement is an excellent option in a subgroup of
patients with BBCs that do not respond to plastic stent
placement or to the usual endoscopic therapies [3, 24–
26]. However, recent papers using FCSEMSs in BBCs
[3, 24–26] reported complications, including duodenal
migration [24, 26], bile duct ulcerations [25], de novo
choledocholithiasis [25], strictures [3, 25], and even pe-
riampullary adenoma [25]. Furthermore, optimal stenting
duration has not been well studied, and long-term stent
placement commonly occurs [3, 19, 25]. Prolonged
FCSEMS placement is associated with the majority of
the complications reported and has not been shown to
increase efficacy [3, 25, 26], except in the treatment of
strictures [3, 24, 27].
This study evaluated the optimal duration of stenting
and the efficacy and safety of temporary FCSEMS place-
ment for the treatment of three BBCs: refractory biliary
leaks, difficult-to-control post-ES bleeding, and perfora-
tions. Our primary hypothesis was that short-term stenting
(30 days or less) would effectively treat the examined
BBCs without the development of early or late
complications.
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Materials and methods
Patients and setting
An interventional endoscopy database was retrospectively
reviewed to identify all of the patients referred for ERCP
who were treated with an FCSEMS as a rescue treatment
for refractory biliary leaks, difficult-to-control post-ES
bleeding, and perforations between March 2007 and May
2011. As an additional inclusion criterion, all stents were
required to have been removed within 30 days of place-
ment. The endoscopic and medical reports and the
radiological findings of these patients were reviewed to
collect the following data: patient demographics, indica-
tion for ERCP, duration of stenting, treatment outcomes,
complications, and specific information for each group of
patients. This study was conducted at a total of four
institutions: three tertiary referral academic centers
(Pulido Valente Hospital, Faculty of Medical Sciences,
Lisbon, Portugal; Cuf Infanto Santo Hospital, Lisbon,
Portugal; Professor Doutor Fernando Fonseca Hospital,
Amadora, Portugal) and one community hospital (Jose´
Joaquim Fernandes Hospital, Beja, Portugal). All patients
provided informed written consent prior to their proce-
dures. Each institutional review board involved approved
this retrospective study.
Definitions
Refractory biliary leaks were defined as leaks that failed
to close after endoscopic intervention with a combination
of biliary sphincterotomy and placement of a large-bore
(10-Fr) transpapillary biliary stent regardless of biliary
leak location (cystic stump, common bile duct/common
hepatic duct, Luschka). All the plastic stents used had, at
least, a length of 7 cm. High-grade biliary leaks were
defined as leaks observed fluoroscopically prior to intra-
hepatic opacification [4]. Ceased bile output was defined
as biliary drainage of less than 5 ml/day in percutaneous
drains.
Difficult-to-control post-ES bleeding was defined as a
hemorrhage where usual endoscopic measures [8, 15, 16]
were attempted but failed to achieve hemostasis. Imme-
diate post-ES bleeding episodes were defined as episodes
that occurred at the time of sphincterotomy [8, 15], while
delayed post-ES bleeding episodes were defined as
bleeding that began hours to several days after the end of
the ERCP procedure [8, 16]. Bleeding severity was graded
as mild, moderate or severe using the following previously
described validated grading system [16]: Mild bleeding
was defined by clinical evidence of gastrointestinal
bleeding, hemoglobin decrease of less than 3 g/dl, and no
need for transfusion, while moderate bleeding was defined
by the need for transfusion (4 units or less); severe
bleeding was defined by the need for transfusion (5 units
or more) or rescue intervention (angiographic or surgical).
Immediate post-ES bleeding that required endoscopic
treatment was considered, at minimum, as mild bleed-
ing. At the time of the procedures, perforations were
recognized by the characteristic contrast extravasation
and retroperitoneal air on computed tomography (CT)
scans, regardless of their association with subcutaneous
emphysema.
Complications were defined as any adverse events
related to FCSEMS placement. Early complications were
defined as complications that occurred while stents were in
place. Early complications, if any, were reported separately
for FCSEMS insertion and removal. Late complications
were defined as those complications that occurred after
FCSEMS removal. Migration (distal or proximal), pan-
creatitis, cholecystitis, bile duct and duodenal ulcerations,
de novo choledocholithiasis, and late strictures were care-
fully monitored using previously defined definitions [16,
20, 23, 25, 27].
Intervention and follow-up
All procedures were performed or supervised by two
experienced pancreatobiliary endoscopists (J.C. and M.L.).
ERCP procedures were performed in the prone position
under sedation with propofol administered by an anes-
thesiologist. All of the endoscopic examinations were
performed using a therapeutic duodenoscope (TJF-160R,
TJF-160 VR, TJF-Q180 V; Olympus, Tokyo, Japan).
Although all FCSEMSs used had a 10-mm luminal
diameter, the length varied from 40 to 80 mm (Tables 1,
2, 3). From March 2007 to December 2009, two different
stents were used: the Hanarostent (M. I. Tech, Seoul,
South Korea) and the Niti-S (Taewoong Medical, Seoul,
South Korea). After January 2010, the Wallflex (Boston
Scientific, Natick, MA, USA) biliary stent was used in all
cases. All patients underwent or had previously undergone
a biliary sphincterotomy prior to FCSEMS placement.
When the gallbladder was still present, FCSEMSs were
placed below the cystic-duct insertion. In patients with
bile leaks, the stent length (Table 1) was selected to
enable leak coverage. After clinical evidence of the
complete resolution of the initial condition, patients were
scheduled for a second ERCP where the FCSEMS was
removed through the scope using rat-toothed forceps or a
cold snare at the discretion of the endoscopist. If, after
pulling the stent, resistance was encountered, the stent was
fixed to the tip of the duodenoscope with the forceps or
the snare, and the instrument and the stent were removed
together. After stent removal, a cholangiogram was per-
formed to evaluate the initial problem and possible ductal
Surg Endosc (2013) 27:313–324 315
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injury. Patients were maintained several days on antibi-
otics due to the initial clinical condition, but not because
of the stent itself. We do not advocate maintaining
patients on antibiotics while covered stents are in place.
With a large-diameter stent in place there is no obstruction
of bile flow and there is no risk of cholangitis. The
majority of patients underwent a follow-up ERCP proce-
dure weeks to months after FCSEMS removal to deter-
mine if late strictures had developed.
At the moment of control ERCP a subset of patients with
normal cholangiogram and previous history of one or more
episodes of transient cholestasis were submitted to chole-
dochoscopy to exclude minor bile duct defects (tissue
hyperplasia). Cholangioscopy procedures were performed
using the ‘‘mother–baby’’ technique. In this approach, a
fiber-optic cholangioscope (CHF-BP30; Olympus, Tokyo,
Japan) connected to a high-resolution system (Olympus,
Tokyo, Japan) was utilized.
Long-term follow-up was obtained by reviewing clini-
cal notes provided by regular clinic visits, laboratory
results, imaging, cholangiography procedures performed
weeks to months after stent removal (when available),
cholangioscopy data, and structured telephone interviews
with patients or family at the time of manuscript
preparation.
Results
A total of 6,267 records for ERCP procedures that occurred
between March 2007 and May 2011 were identified in the
endoscopy database. Twenty-nine patients who met the
inclusion criteria were identified. Four of these patients
were excluded for the following reasons: incomplete data
concerning endoscopic procedures and follow-up (three
patients) and unavailability of informed written consent
(one patient).
A total of 25 patients (9 male and 16 female) with a
median age of 55 years (range 29–91 years, mean
56.2 years) were enrolled in the study. All stents were
safely removed with a snare or rat-toothed forceps.
Complete resolution of the initial BBC was con-
firmed in all patients. Patients were followed up for a
median of 123.5 weeks (range 14–214 weeks, mean
113.3 weeks) following FCSEMS removal. One patient
in the post-ES bleeding group was lost to follow-up
because he underwent surgery for an ampullary tumor
and died 5 days post surgery. Nevertheless, he was
included in the study because his FCSEMS was removed
and his initial clinical condition had resolved. All other
patients completed the follow-up. For further detailed
analysis, patients were divided into the following three
Table 1 Demographics, indications, detailed treatment data, and follow-up for patients with refractory biliary leaks
Age
(years)/
sex
Origin
of leak
Time interval (days) between
ES ? plastic stent (initial ERCP)
and FCSEMS delivery
External drain bile
output ceased (days
after FCSEMS)
Duration of stenting
(days)/ FCSEMS
length (cm)
Follow-up (weeks)/control
ERCP (weeks)/
choledochoscopy (yes/NA)
39/F CBD/CHD 12 6 18/8 14/NA/NA
45/M Cystic stump 10 2 28/6 30/24/yes
38/M CBD/CHD 10 8 21/8 52/48/yes
32/M CBD/CHD 8 6 18/8 104/90/yes
73/F Cystic stump 18 3 20/6 36/30/NA
47/F CBD/CHD 14 5 21/8 124/110/yes
73/F Cystic stump 7 2 7/6 208/50/NA
84/M Cystic stump 14 2 14/6 206/52/NA
62/F Cystic stump 7 2 14/6 205/70/NA
74/F Cystic stump 7 3 14/8 214/54/NA
89/F Cystic stump 7 2 14/6 154/100/NA
62/F Cystic stump 7 3 14/8 123/60/NA
39/F Cystic stump 8 4 15/8 165/NA/NA
48/M Cystic stump 10 3 15/6 180/NA/NA
42/F Cystic stump 10 3 16/6 125/NA/NA
55/F Cystic stump 12 4 16/8 130/NA/NA
64/M CBD/CHD 10a 5 18/8 104/NA/NA
F female, M male, CBD/CHD common bile duct/common hepatic duct, ES endoscopic sphincterotomy, ERCP endoscopic retrograde cholan-
giopancreatography, FCSEMS fully covered self-expandable metal stent, NA not available
a Patient was submitted, on day 6, to a second ERCP to place a second large-bore plastic stent
316 Surg Endosc (2013) 27:313–324
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groups that were defined earlier in the ‘‘Materials and
methods’’ section: refractory biliary leaks (Table 1),
postsphincterotomy bleeding (Table 2), and perforations
(Table 3).
Refractory biliary leaks
FCSEMSs were placed in 17 patients with postcholecys-
tectomy refractory biliary leaks. The median patient age
Table 2 Clinical characteristics and treatment data of patients with postsphincterotomy bleeding
Age
(years)/
sex
Indication Comorbid
conditions/risk
factors for
bleeding
PT (s/INR)/
platelet
count
(100,000/ll)
Bleeding
time after
ERCP
(days)/type
No. of units of
blood
transfusions/Hg
drop (g/dl)
Attempted
treatments
Duration of
stenting (days)/
FCSEMS length
(cm)
Follow-up/
control
ERCP
(weeks)
91/F Stones Atrial fibrillation
anticoagulation
therapya
17.6/1.4/195 7/clot,
oozing
2/NA Epinephrine
injection,
balloon
tamponade
3/4 20/14
37/M Stones Hepatitis C; no
evidence of
cirrhosis
10.8/1.0/239 3/clot,
oozing
0/2,4 Epinephrine
injection,
endoclips
6/6 16/14
80/F Stones Periampullary
diverticulum
12.4/1.2/231 Immediate/
pulsatile
0/1.3 Epinephrine
injection,
balloon
tamponade
6/6 14/12
40/M Ampullary
tumor
Hepatitis B 11.0/1.0/207 2/clot,
oozing
10/NA Epinephrine
injection
15/6 NAb
AIDS
Mycobacterium
avium complex
F female, M male, PT prothrombin time, INR international normalized ratio, Hg hemoglobin, ES endoscopic sphincterotomy, ERCP endoscopic
retrograde cholangiopancreatography, ICU intensive care unit, NA not available, AIDS acquired immune-deficiency syndrome
a Patient was receiving anticoagulant therapy within 4 days of procedure. Anticoagulants were held for 5 days post procedure and for five more
days after stent removal
b Patient was submitted to surgery for ampullary tumor and died 5 days post surgery
Table 3 Characteristics, treatment, and outcome data of patients with perforations
Age
(years)/
sex
Indication Motive of perforationa Perforation
diagnosis
Number
of days
in ICU
Duration of
stenting
(days)/FCSEMS
length (cm)
Follow-up (weeks)/
control ERCP (weeks)/
choledochoscopy (yes/
NA)
55/F Stones Zipper cut ES with bleeding
and attempted balloon
tamponade
Subcutaneous emphysema
Extravasation of contrast
Retroperitoneal air on CT
scan
4 21/4 108/66/yes
29/F Stones Zipper cut ES Extravasation of contrast
Retroperitoneal air on CT
scan
1 30/6 72/48/yes
31/M Stones Large balloon dilation followed
by attempted removal of
stones
Extravasation of contrast
Retroperitoneal air on CT
scan
2 30/6 160/58/NA
76/F Stones Zipper cut ES Subcutaneous emphysema
Extravasation of contrast
Retroperitoneal air on CT
scan
3 29/6 156/48/NA
F female, M male, ES endoscopic sphincterotomy, ERCP endoscopic retrograde cholangiopancreatography, ICU intensive care unit, NA not
available
a According to the endoscopist who performed the procedures
Surg Endosc (2013) 27:313–324 317
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was 55 years (range 32–89 years, mean 56.8 years). Final
diagnoses included 12 cystic-stump high-grade leaks and
five common bile duct/common hepatic duct leaks. During
the first ERCP procedure, all patients had high-grade leaks
(four), and they were treated with a combination of biliary
sphincterotomy and placement of a large-bore (10-Fr)
transpapillary biliary stent, at least 7 cm long. Patients who
were nonresponsive to the initial endoscopic therapy were
identified according to clinical grounds and individual
assessment. Similar or increased levels of percutaneous
drainage and worsening images were the most commonly
utilized criteria to determine endoscopic treatment failure.
The second ERCP procedure with FCSEMS placement was
performed after a median time interval of 10 days (range
7–18 days, mean 10.1 days) after the first procedure. One
patient had a second ERCP on day 6 post ERCP to place a
second large-bore (10-Fr) plastic stent without success,
leading to FCSEMS placement on day 10 post ERCP.
Subsequent to FCSEMS placement, percutaneous drain
output ceased after a median time of 3 days (range
2–8 days, mean 3.7 days). When comparing the drainage
output of the common bile duct/common hepatic duct leaks
with the cystic-stump leaks, drainage ceased more quickly
in the patients with cystic-stump leaks, with a median time
to cessation of 3 days compared with 6 days. FCSEMSs
were removed after a median time of 16 days (range
7–28 days, mean 16.6 days). Follow-up was completed for
all patients after a median time of 125 weeks (range
14–214 weeks, mean 127.8 weeks).
The five patients with common bile duct/common
hepatic duct leaks exhibited major bile duct injuries with
associated strictures detected at the time of the first ERCP.
After FCSEMS removal, patients were treated with mul-
tiple plastic stents for 9–12 months. Four patients had
clinical resolution of their strictures while maintaining
minor bile duct defects, and one patient was still in endo-
scopic treatment at the time of manuscript preparation.
Postsphincterotomy bleeding
FCSEMSs were placed in four patients with difficult-to-
treat post-ES bleeding. Patients had a median age of
60 years (range 37–91 years, mean 62 years). Bleeding
was immediate in one patient with a periampullary diver-
ticulum (Fig. 1) and was delayed in three patients, occur-
ring on days 2, 3, and 7 post ERCP. All patients were
submitted to endoscopic measures to achieve hemostasis
without success. Two hemorrhages were considered minor,
with both patients exhibiting melena and hemoglobin drop;
moderate and severe bleeding were observed in the
remaining two patients. The first three patients underwent
the second ERCP procedure on the day following clinical
presentation of bleeding. In the patient with severe
bleeding, the second ERCP procedure was delayed 4 days
(due to a long holiday weekend). We hypothesize that the
delay in treatment was the main cause of the severity of
bleeding; the patient required the transfusion of 10 units of
blood. Following FCSEMS placement, there were no signs
or symptoms of recurrent gastrointestinal (GI) bleeding.
Stents were removed after a median time of 6 days (range
3–15 days, mean 7.5 days). Follow-up was completed for
three patients after a median time of 16 weeks (range
14–20 weeks, mean 16.7 weeks).
Perforations
Four patients with a median age of 43 years (range
29–76 years, mean 47.8 years) underwent FCSEMS
placement as a rescue therapy for perforation closure
following endoscopic biliary sphincterotomy. All the
perforations were recognized at the time of the procedure
based on characteristic contrast extravasation. All patients
had a CT scan showing retroperitoneal air and leaks, and
two patients exhibited associated subcutaneous emphy-
sema (Fig. 2). According to the endoscopist who per-
formed the procedures, a zipper cut during ES was the
most common cause of perforation. None of the patients
underwent precut papillotomy, which has been suggested
as a risk factor for perforation [10]. The four patients were
admitted to the intensive care unit (ICU) and treated with
intravenous antibiotics, fluids, and a nil-by-mouth regi-
men. The median length of ICU stay was 2.5 days (range
1–4 days). The two patients with subcutaneous emphy-
sema required mechanical ventilation for bilateral pneu-
mothorax for 1 day. Patients were discharged from the
hospital after a median of 10 days (range 7–12 days) post
FCSEMS placement, and stent removal was performed as
an outpatient procedure. FCSEMSs were left in place for a
median time of 29.5 days (range 21–30 days, mean
27.5 days). Follow-up was completed for all patients after
a median time of 132 weeks (range 72–160 weeks, mean
124 weeks).
Complications and follow-up
There were no initial complications related to FCSEMS
placement or removal. Four patients, two in the post-ES
bleeding group and two in the perforation group, exhibited
two- to threefold increases in serum amylase values in the
absence of pain following FCSEMS placement; these
increases were assumed to be a consequence of the ERCP
procedures. At the time of extraction, the endoscopist
thought that seven stents had slid several millimeters into
the duodenum. Because the largest portion of the stent
was still inside the bile duct and there was clinical reso-
lution of the initial conditions, these movements were not
318 Surg Endosc (2013) 27:313–324
123
considered stent migration. None of the five patients (two
in the bleeding group and three in the perforation group)
who had an intact gallbladder presented with cholecystitis.
There were no cases of duodenal ulcerations or de novo
choledocholithiasis found within FCSEMS and bile duct at
the time of stent removal.
During the long-term follow-up of the 24 patients, bile
leak recurrence, episodes of rebleeding, or delayed com-
plications (e.g., abscesses or strictures) related to perfora-
tions were not observed in any of the patients. Follow-up
ERCP procedures were performed in 18 patients (11 in the
bile leak group, 3 in the bleeding group, and 4 in the
perforation group) after a median time of 51 weeks (range
12–110 weeks, mean 52.7 weeks). In 15 patients, the
results of the ERCP were normal. The other three patients
had minor stricture/bile duct defects that were without
clinical significance and were related to injuries obtained
during cholecystectomy. When the bile duct dimensions at
the moment of FCSEMS placement and the follow-up
cholangiography performed months later were compared,
there was no evidence of bile duct enlargement due to
FCSEMS placement. In the 25 patients mid bile duct
diameter was initially measured with values ranging from 6
to 12 mm. After FCSEMS placement the bile duct assumed
the shape and diameter of the stent (for bile duct\10 mm),
returning to normal after FCSEMS removal.
Fig. 1 Use of fully covered self-expandable metal stent (FCSEMS)
for treatment of difficult-to-control bleeding immediately after
sphincterotomy: A Endoscopic image of active bleeding after biliary
sphincterotomy in a patient with a periampullary diverticulum.
B Endoscopic lateral view of a fully deployed FCSEMS that resulted
in mechanical tamponade and hemostasis. Note the blue tone of the
papilla of Vater after epinephrine injection. C Inside view of a
FCSEMS across the ampullary orifice showing the immediate
tamponade of the bleeding site. D Fluoroscopic image of a FCSEMS
removal through the scope
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Cholangioscopy procedures were performed in six
patients (four in the bile leak group and two in perforation
group). In the perforation group patients and in one of the
bile leak group patients who had a cystic-stump leak
(Video 1), the choledochoscopy results were normal
without evidence of minor bile duct defects or tissue
hyperplasia. The other three patients, who presented with
bile duct/common hepatic duct leaks, exhibited minor
strictures (fibrous ring) of the bile duct at the site of
strictures being treated with long-term plastic stenting.
Above the minor defect/stricture, in the place where the
initial portion of the FCSEMS was placed, no defects or
evidence of reactive tissue hyperplasia were observed
(Video 2).
Discussion
According to our findings, temporary placement of a
FCSEMS for 30 days or less is an effective rescue therapy
for several BBCs and is free from early complications. The
median time of FCSEMS removal varied depending upon
the BBC; FCSEMSs were removed after 6 days in patients
with difficult-to-control post-ES bleeding, after 16 days in
patients with complex biliary leaks, and after 29.5 days in
patients with perforations. Patients underwent long-term
follow-up, including cholangiography and cholangioscopy
procedures, without evidence of late complications. These
results suggest that the short duration of stenting was a key
factor for the absence of FCSEMS-related complications.
Bile leaks after cholecystectomy are traditionally man-
aged with endoscopic techniques consisting of transpapil-
lary placement of large-bore (10-Fr) plastic stents with or
without biliary sphincterotomy [4, 5, 19, 22]. For simple
leaks such as small cystic duct leaks (low-grade leaks) and
Luschka’s duct leaks, the success rate of endoscopic
treatment is high. Bile leak closure is achieved because the
transpapillary high-pressure gradient is decreased or elim-
inated with the endoscopic procedures. However, in a small
subset of patients with more complex leaks (high-grade
cystic-stump leaks, common bile duct/common hepatic
duct leaks, bile leaks after liver transplantation or large
leaks following partial cholecystectomy) successful closure
can be more problematic, leading to an increased number
of procedures or even surgery [4, 5, 19, 22]. Refractory bile
leaks can be treated by FCSEMS. The large stent diameter
diverts more flow away from the leak site, causing a sig-
nificant decrease of the pressure gradient at the ampullary
level. Furthermore, the FCSEMS directly covers the leak
site. Baron et al. [19] first reported the use of partially
(n = 2) and fully covered (n = 1) SEMSs in three patients
with complex biliary leaks of the gallbladder bed following
open subtotal cholecystectomy procedures. In two patients,
the leaks had not responded to the endoscopic intervention
of a combination of ES and a large-bore plastic stent; in the
third patient, a FCSEMS was the initial option. Stents were
removed 9, 5, and 3 weeks later, and no major complica-
tions were reported. The authors suggested that, until more
data were available, stents should remain in place for an
arbitrary time of B3 months. Interestingly, bile drainage
output decreased markedly in 1 week or less following
SEMS placement.
A study with 16 patients used partially covered SEMS to
treat 8 cystic-stump leaks, 5 Luschka’s duct leaks, 2 partial
cholecystectomy leaks, and 1 liver transplant anastomotic
leak [20]. These patients had previously undergone
unsuccessful plastic stent placement or had severe comor-
bidities that prevented multiple interventions. Of the
patients studied, 15 responded to partially covered SEMS
placement. Stents were left in place for a median time of
3 months (range 1–17 months), and the authors reported
complications in two patients (one proximal and one distal
migration). Information regarding external drainage or
Fig. 2 CT scan images following postsphincterotomy perforation:
A CT scan of the chest. Axial view showing bilateral pneumothorax,
pneumomediastinum, and subcutaneous emphysema. B CT scan of
the abdomen. Axial view showing significant pneumoperitoneum and
retroperitoneal air. The fully covered self-expandable metal stent that
was used to seal the perforation can be seen in the bile duct
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recommendations concerning stenting duration were not
available.
Wang et al. [25] reported the first case series using
FCSEMS to treat a heterogeneous group of patients with
complex leaks that were defined as biliary leaks that failed
ERCP intervention, bile leaks after cadaveric orthotopic
liver transplantation, and complicated cholecystectomies
with large bile leaks. The bile leaks in all 13 patients
resolved, and FCSEMSs were removed in 11 patients after
a median time of 103 days (range 67–493 days). However,
several complications were reported. Ten of the 11 patients
had de novo choledocholithiasis within the FCSEMS. Two
patients presented with strictures that developed after stent
removal; the strictures were located at the previous location
of the proximal edge of the FCSEMS. One of the strictures
required treatment with balloon dilation and stent place-
ment for 7 months. In five of seven patients who underwent
choledochoscopy at the time of stent removal, ulceration
was seen where the fins anchored the stent into the bile
duct. Again, no information regarding external bile drain
output was available. The authors advocated that the stents
may be reasonably left in place for more than 6 weeks.
In a prospective study of FCSEMS placement for a
variety of BBCs [3], one patient with a large intrahepatic
fistula after excision of a hydatid cystic was treated with a
FCSEMS. The FCSEMS remained in place for 36 days,
despite the fact that external drainage stopped 24 h after
insertion. In a recent case report [28], a patient with a
Luschka’s duct leak treated with an FCSEMS after
unsuccessful endoscopic management with ES and plastic
stent placement had the stent removed after 28 days.
Again, the authors reported an almost immediate decrease
in the bile output from the percutaneous drain.
In this study, we examined two types of refractory bil-
iary leaks that exhibited a 100 % success rate following
FCSEMS treatment, comparable to other reports using
partially or fully covered SEMS [19, 20, 25]. The leaks in
our study (high-grade cystic-stump leaks or common bile
duct/common hepatic duct leaks) failed initial endoscopic
treatment with placement of large-bore (10-Fr) plastic
stents and biliary sphincterotomy which has been reported
by other studies [5, 19, 20, 25]. A variety of endoscopic
techniques other than placement of FCSEMS could have
been chosen in the cases presented here. One option is the
placement of multiple large-bore (10-Fr) plastic stents at
lower cost to further decrease transpapillary high pressure
gradient. However, plastic stents can occlude possibly
before leak closure, and furthermore one of our patients
was treated with two large-bore plastic stents without
success, increasing costs and leading to another ERCP for
FCSEMS placement. In our series, the bile output from the
percutaneous drains ceased after a median time of 3 days
(range 2–8 days) following FCSEMS placement. This
result is comparable to earlier studies [3, 19, 28], sug-
gesting that stents could be removed earlier than previously
reported (for both partially and fully covered SEMS). In
our study, stents were removed after a median time of
16 days, which deviated from earlier studies [20, 25]. The
median time interval between ceased biliary drainage and
FCSEMS removal was 12 days (range 5–26 days). Bile
drainage ceased after 2–4 days (median 3 days) for cystic-
stump leaks, while bile drainage for even more complex
leaks associated with major common bile duct/common
hepatic duct injuries ceased between 5 and 8 days (median
6 days) following FCSEMS placement. Upon FCSEMS
removal, leaks were sealed in all cases, suggesting that
stents can be removed safely 10–15 days after cessation of
bile drainage. Taken together, these findings suggest that,
for refractory bile leaks, stents can be safely removed after
no longer than 3 weeks.
In a recent report [26], five patients were treated with
temporary FCSEMSs for difficult-to-control post-ES
bleeding. The stent worked through mechanical tamponade
of the bleeding site. Three patients were treated for
immediate bleeding, and two patients were treated for
delayed hemorrhage. Four patients were previously sub-
mitted to other endoscopic measures (including emboliza-
tion in one patient) but failed to achieve hemostasis. The
stents were removed in three patients at 2, 4, and 8 weeks;
stents had completely migrated spontaneously without
complications in two patients at 4 weeks. No other
complications were reported. The authors estimated that a
2–4-week duration of FCSEMS placement would be
appropriate in this setting.
We studied a cohort of patients submitted to FCSEMS
placement after the failure of several endoscopic treatments
for post-ES bleeding. Two mild cases, one moderate case,
and one severe case of bleeding were treated. This treat-
ment resulted in immediate hemostasis in all patients, and
no further interventions were needed, which is consistent
with the report of Shah et al. [26]. In our study, patients
with post-ES bleeding had their stents removed after a
median time of 6 days. In one patient in whom the stent
remained in place for 3 days, anticoagulant therapy was
resumed 5 days after stent removal, and no signs of reb-
leeding were observed. In a study by Shah et al. [26],
anticoagulants were resumed with stents in place, and again
no signs or symptoms of recurrent GI bleeding were
detected. Because the hemostatic effect appears to be
immediate and stenting works through a tamponade effect,
this result suggests that stents can be safely removed no
longer than 1 week after placement and patients with
anticoagulant therapy can resume therapy while stents are
in place. The repeated instrumentation on a very short time
scale can be considered aggressive, and perhaps stents
could be removed later. However, the intention in
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removing the stents early is to repeat the procedure before
discharging the patient from hospital. The early removal
avoids the return of the patient to the hospital as an out-
patient. Furthermore, the early removal of the stent avoids
potential complications, namely migration of the stent.
Garcia-Cano et al. [3] used an FCSEMS to close two
perforations after ES. Patients were managed conserva-
tively, and stents were removed after a mean time of
96 days. The covering seals the perforation, perhaps with a
strong occlusion pressure, allowing for a safe and faster
recovery. We used FCSEMS to treat four perforations. All
patients were admitted to the ICU, and two patients
required mechanical ventilation. Perforations were detected
during ERCP procedures on account of large extravasation
of contrast in all four patients and subcutaneous emphy-
sema in two patients leading to respiratory failure, sug-
gesting that perforations were severe. With the FCSEMS
approach, all patients recovered rapidly and resumed oral
feeding less than 1 week after perforation detection. Fur-
thermore, the patients were rapidly discharged from hos-
pital, and FCSEMS removal, which occurred after a
median time of 29.5 days, was performed as an outpatient
procedure. More importantly, no complications, such as
papillary strictures or abscesses, were detected during
follow-up. These data suggest that FCSEMSs are effective
in treating post-ES perforations and are associated with
rapid, complication-free recovery. We do not advocate
SEMS placement for microperforations with minor retro-
peritoneal air where most patients will do well with med-
ical management and placement of a plastic stent. We
suggest the use of FCSEMS in more severe perforations
with major leaks and/or subcutaneous emphysema detected
at the time of ERCP. The stents were removed within
30 days of placement, but eventually, due to the rapid
recovery of all patients in our series, stents can be removed
even earlier (i.e., before discharge from hospital).
The majority of patients had a follow-up ERCP fol-
lowing FCSEMS removal. These examinations were
scheduled by treating physicians to evaluate possible late
bile duct injury several months after stent removal. Con-
cerns have been raised in literature [3, 25, 29] about the
development of late strictures several months after FCS-
EMS removal, and this was the main cause for the referral
of patients to a control ERCP. Patients contacted the
authors for further information about the development of
late strictures and possible methods for diagnosis. They
were told that a control ERCP may not be the standard of
care because it is an invasive procedure and could be
avoided by carrying out magnetic resonance imaging
(MRI) associated with periodic blood samples. However,
18 patients chose to undergo a control ERCP, providing
informed written consent before this additional procedure.
No concerns were raised by each institutional review board
that approved this study. Seven patients did not undergo the
follow-up ERCP; one patient died, one patient was still in
endoscopic treatment at the time of manuscript preparation,
and the remaining five patients declined further endoscopic
procedures despite being available for follow-up using the
MRI strategy associated with blood samples.
The FCSEMS used had no fins for anchoring. Never-
theless, the proximal edge of the stent can potentially cause
bile duct damage, leading to reactive tissue hyperplasia and
possibly to the development of a late stricture. Although
this stent effect on the biliary epithelium may be related to
long-term stent placement, we intended to exclude this
possibility after short-term stenting with cholangioscopy
screenings. At the time of follow-up ERCP, patients with
normal cholangiogram but who had previous history of at
least one episode of transient cholestasis were submitted to
cholangioscopy to determine if tissue hyperplasia/minor
bile defects had developed. Choledochoscopy results were
normal in three patients. The other three patients had pre-
viously been treated for a stricture caused at the time of
cholecystectomy. In all cases, there were no bile duct
lesions above the remaining minor stricture, which had an
endoscopic appearance of a fibrous ring.
Patients with bile duct/common hepatic duct leaks had
associated strictures, and their FCSEMSs were removed
following the clinical resolution of leaks. Strictures were
subsequently treated by multiple placements of plastic
stents (not FCSEMS). Although reports exist suggesting
that temporary FCSEMS placement in benign strictures
offers a potential alternative to the multiple plastic stent
strategy [21, 24, 27], these findings have been challenged
in literature [30]. We treated seven patients with benign
biliary strictures using FCSEMS (unpublished data), and
we observed complications in six patients. Three patients
developed de novo choledocholithiasis and stent occlusion,
one patient exhibited proximal stent migration, and two
patients exhibited distal stent migration. The FCSEMS
were removed, and the patients were subsequently treated
with multiple plastic stents. Until more data are available,
we use plastic stents to treat benign biliary strictures.
When FCSEMS placement is considered for BBCs, cost
is an important issue. Although no studies are available on
this matter, FCSEMS placement as a rescue therapy is
likely to be cost-effective because the prevention of several
procedures (including surgery) offsets the cost of the stents.
Complications have been reported in papers using FCS-
EMS to treat BBCs [3, 24–27]. One common complication
is stent migration, which has been reported previously
[24, 26]. Stent migration is associated with short stents
(i.e., 4 cm) that tend to migrate easily. In our series we did
not observe any migration and we only used two short
stents in two patients with an intact gallbladder and low
cystic-duct insertion. In our study complications did not
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develop in any patients following FCSEMS placement.
Furthermore, after long-term follow-up, no patients
exhibited signs of FCSEMS-related complications. We
believe that most of the FCSEMS-associated complications
are related to the duration of stenting, especially the nearly
10 % stricture rate of the literature [3, 25, 29], which is a
major concern before additional FCSEMS placement for a
refractory biliary leak. The association between short-term
stenting and the absence of complications strongly support
this hypothesis. A subset of our patients underwent one
additional ERCP after FCSEMS removal on account of
safety reasons. As suggested by our study, short-term
placement of FCSEMS is safe and we do not advocate
control ERCPs in the future for patients submitted to short-
term (i.e., 30 days or less) FCSEMS placement.
Several limitations of our study should be taken into
account. This was a retrospective study where stent
removal was not scheduled according to specific endpoints.
In the leak group, no patients with bile leaks after cadaveric
orthotopic liver transplantation or with large leaks fol-
lowing partial cholecystectomy were included; these types
of leaks can be problematic, leading to increased stenting
durations [22, 25, 29, 31]. Nevertheless, in a report of three
patients outlining the SEMS treatment of bile leaks after
open subtotal cholecystectomy, Baron et al. [22] noted a
dramatic decrease of bile output in a short period of time,
suggesting that these leaks can also be treated with short-
term stenting. Patients with post-ES bleeding had a shorter
follow-up compared with the other groups; the effect of the
stents appeared to be immediate, and very late rebleeding
was unusual. These patients had a median time of stenting
of 6 days, and there was no evidence that such very short-
term stenting was associated with late bile duct injury. We
suggest that further studies are needed with a prospective
design, where time of stent removal should be a primary
endpoint. In these proposed studies, biliary drainage should
be carefully monitored and used as a marker for scheduled
stent removal in patients experiencing bile leakage.
The strengths of our study are the early removal of
stents, the long-term follow-up, the use of control cholan-
giography and choledochoscopy procedures in a subset of
patients, and the relatively large sample size. To our
knowledge, this is the first study concerning the duration of
FCSEMS placement and the largest series of patients
treated with FCSEMS for BBCs other than benign
strictures.
In conclusion, our data suggest that FCSEMS placement
for 30 days or less is efficacious at resolving complex
biliary leaks, difficult-to-control post-ES bleeding, and
perforations. Duration of stenting should be different for
each type of condition. Stents can be safely removed, and
short-term stenting is associated with the absence of early
and late complications.
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